NCT01016340View on ClinicalTrials.gov

Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

June 30, 2013

Conditions
Male Oligoasthenospermia
Interventions
DRUG

MCS

MCS-5 Softgel 5 mg

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Health Ever Bio-Tech Co., Ltd.

INDUSTRY